The logo of GlaxoSmithKline Plc sits on a sign outside the pharmaceutical company's headquarters in London, U.K., on Tuesday, April 22, 2014. Novartis AG agreed to buy GlaxoSmithKline's cancer drugs for as much as $16 billion while selling most of the company's vaccines division to Glaxo for $7.1 billion and its animal-health unit to Eli Lilly & Co. for $5.4 billion. Photographer: Matthew Lloyd/Bloomberg via Getty Images
Getty Images

Bloomberg Bloomberg